Dupixent approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis

▴ Dupixent approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
Atopic dermatitis is a chronic inflammatory disease of the skin that can be debilitating, and severe disease can significantly impact many aspects of life for both children and their families.

The European Commission (EC) has extended the marketing authorization for Dupixent (dupilumab) in the European Union (EU) to include children 6 to 11 years of age with severe atopic dermatitis who are candidates for systemic therapy. Dupixent is the only systemic medicine approved in the EU to treat these patients.

"As the parent of a child with atopic dermatitis, and someone who works with families impacted by this condition daily, I’ve seen first-hand the enormous physical and mental health burden of this disease, and the toll it can take on the entire family,” said Korey Capozza, MPH, Founder and Executive Director of Global Parents for Eczema Research (GPER). “Young children with severe atopic dermatitis currently have few treatment choices and significant unmet needs. We welcome the addition of new medicines for these underserved patients."

Atopic dermatitis is a chronic inflammatory disease of the skin that can be debilitating, and severe disease can significantly impact many aspects of life for both children and their families. The current standard of care for children with severe atopic dermatitis in Europe is limited to topical treatments, leaving those with poorly controlled disease to cope with intense, unrelenting itch and skin lesions that can cover much of the body, resulting in skin cracking, redness or darkening, crusting and oozing. In addition, uncontrolled severe atopic dermatitis can have a substantial emotional and psychosocial impact, causing sleep disturbance, symptoms of anxiety and depression and feelings of isolation in children.

 “The approval of Dupixent for children in Europe marks another significant milestone for atopic dermatitis patients and their families, broadening the availability of a first-in-class medicine that offers a proven safe and effective treatment for this debilitating skin disease,” said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi. “Dupixent’s ability to provide significantly clearer skin, and clinically meaningful reduction of persistent itch, addresses important unmet needs for these children. In addition to atopic dermatitis, we continue to investigate the potential of Dupixent in younger age groups and across a variety of type 2 inflammatory diseases.”

Dupixent is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins, and is not an immunosuppressant. Data from Dupixent clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP).

“This approval for Dupixent in the EU represents a major advancement for children with severe atopic dermatitis and their families, who spend countless days and nights tending to their child’s disease with few treatment options to help alleviate the debilitating symptoms,” said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer at Regeneron. “Dupixent is a novel therapy that addresses a root cause of atopic dermatitis by specifically targeting the underlying type 2 inflammation of the disease. Dupixent has already been used by hundreds of thousands of patients around the world, including those with atopic dermatitis as well as other type 2 inflammatory diseases such as asthma and adults with chronic rhinosinusitis with nasal polyps.  We are pleased to bring this paradigm-changing medicine to even younger patients in the EU who need new options beyond steroids or immunosuppressants.”

In children aged 6-11 years weighing 15 to <60 kg="" dupixent="" 300="" mg="" is="" administered="" as="" an="" injection="" under="" the="" skin="" subcutaneous="" injection="" every="" four="" weeks="" following="" the="" initial="" loading="" dose="" given="" as="" two="" injections="" 14="" days="" apart="" for="" those="" weighing="" span=""> >60 kg, Dupixent 300 mg is administered every two weeks following the initial loading dose given the same day. The dose may be increased to 200 mg every two weeks in patients weighing 15 to <60 kg="" based="" on="" physician="" s="" assessment="" p="">

Tags : #LatestSanofiNewsNov30 #LatestPharmaNewsNov30 #TreatmentforAtopicDermatitis

About the Author


Sana Farid Khan

“The best way to become acquainted with a subject is to write about it."
A confident counselor, a speaker, and an educator, ready to utilize my communication skills effectively in the world of healthcare by putting pen to paper to reach new heights of success.
You can write to me at [email protected]

Related Stories

Loading Please wait...
-Advertisements-




Trending Now

Dr. Priti Mehta, a Pediatric hematologist Oncologist explains the facts about Pre-implantation genetic diagnosisJanuary 21, 2021
The best way to lose weight is to not think about losing weight says Karishma Shah, Nutrition ConsultantJanuary 21, 2021
Demystifying Greenfield Pharma projects and Investment for the beginnersJanuary 21, 2021
Maharashtra COVID Update: Over 50,000 given COVID vaccine shots in three sessions so far January 21, 2021
1,12,007 beneficiaries vaccinated against Coronavirus, covering 11% health workersJanuary 21, 2021
Kerala continues to report surge in COVID cases with 6815 new casesJanuary 21, 2021
US studies claims vaccines are effective against the new Covid-19 strains January 21, 2021
Madhya Pradesh: Bird Flu virus found in 32 districts of state so farJanuary 20, 2021
Karnataka Health Minister expresses hope of launching Arogya Karnataka emergency health servicesJanuary 20, 2021
India starts shipments of Made in India COVID-19 Vaccines to neighbouring countriesJanuary 20, 2021
COVID-19 recovery rate improves to 98.13 pct in JharkhandJanuary 20, 2021
National COVID-19 recovery rate improves to 96.70 per centJanuary 20, 2021
Benefits of coconut waterJanuary 20, 2021
The RSA Group welcomes Eleanor Davies as Managing PartnerJanuary 19, 2021
Mask-wearing linked to reduced COVID-19 transmission, US modelling study suggestsJanuary 19, 2021
Tessa Therapeutics receives PRIME designation from EMA for CD30 CAR-T TherapyJanuary 19, 2021
FUJIFILM Diosynth Biotechnologies begins production of two COVID-19 vaccinesJanuary 19, 2021
Fried food intake linked to heightened serious heart disease and stroke riskJanuary 19, 2021
‘’What is more dangerous is that we don't have any kind of criteria to be a coach,’’ says Parag Patil, Founder, LetzRun India, and MaxFit IndiaJanuary 19, 2021
‘’The younger generation must understand that health and fitness is at least a Forty-year commitment, and not a four-month game,’’ says Shreeharsh Deshmukh, Trainer, and Nutritionist, The Fit problemJanuary 19, 2021